Suppliers and packagers for lupkynis

lupkynis

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716	NDA	Aurinia Pharma U.S., Inc.	75626-001-02	3 PACKET in 1 CARTON (75626-001-02) / 4 BLISTER PACK in 1 PACKET (75626-001-01) / 15 CAPSULE in 1 BLISTER PACK	2021-01-22

Lupkynis (Voclosporin) Supply Chain Analysis

Last updated: February 19, 2026

Lupkynis, the first FDA-approved oral calcineurin inhibitor, is used in combination with a corticosteroid and an immunosuppressant for the treatment of adult patients with active lupus nephritis. The efficacy of voclosporin in this indication is supported by the AURORA 1 and AURORA 2 clinical trials, demonstrating statistically significant improvements in renal response rates compared to placebo.

Who Manufactures Lupkynis?

The commercial manufacturing of Lupkynis is handled by Viatris Inc. Viatris acquired the rights to manufacture and commercialize voclosporin in the U.S. from Aurinia Pharmaceuticals Inc. in August 2021. This agreement covers the finished dosage form of Lupkynis. Viatris operates a global network of manufacturing facilities, with specific sites dedicated to sterile injectables and oral solid dosage forms like Lupkynis.

What are the Key Components of Lupkynis?

Lupkynis is a novel, proprietary immunosuppressant. Its active pharmaceutical ingredient (API) is voclosporin. Voclosporin is a synthetic analog of cyclosporine, but it possesses a distinct pharmacokinetic and pharmacodynamic profile. Key structural features of voclosporin include an altered amino acid sequence at position 4 in the cyclosporine ring, which contributes to its improved absorption and reduced variability.

Where is Voclosporin API Produced?

The upstream manufacturing of voclosporin API is conducted by Lonza Group AG. Lonza, a global contract development and manufacturing organization (CDMO), is responsible for the complex chemical synthesis of voclosporin. The production of complex peptide-based APIs like voclosporin requires specialized capabilities in fermentation and chemical synthesis, which Lonza provides. Lonza's facilities adhere to Good Manufacturing Practices (GMP) to ensure the quality and purity of the API.

What is the Relationship Between Aurinia Pharmaceuticals and Viatris/Lonza?

Aurinia Pharmaceuticals Inc. is the originator of Lupkynis and voclosporin. Aurinia developed the drug and obtained regulatory approvals. Under the terms of their agreement, Aurinia retains certain rights and responsibilities, but the commercial manufacturing and supply of the finished drug product are managed by Viatris, with Lonza as the API supplier.

What are the Supply Chain Risks for Lupkynis?

The supply chain for Lupkynis, like any pharmaceutical product, faces inherent risks. These include:

• API Sourcing and Manufacturing: Reliance on a single API manufacturer, Lonza, presents a concentration risk. Any disruption at Lonza's facilities, due to regulatory issues, operational failures, or geopolitical events, could impact voclosporin availability. Lonza's primary API manufacturing sites for this product are located in Europe.
• Finished Dosage Form Manufacturing: Viatris's manufacturing network is global. While this offers redundancy, it also introduces risks related to logistics, international trade regulations, and country-specific GMP compliance. Any single site responsible for a critical step in the formulation or packaging of Lupkynis could become a bottleneck.
• Regulatory Compliance: Both API and finished drug product manufacturing are subject to stringent regulatory oversight from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Non-compliance at any stage could lead to product recalls, manufacturing halts, or import alerts.
• Intellectual Property: While voclosporin is patented, the long-term market exclusivity relies on continued patent protection and the absence of generic competition. Expiring patents or successful patent challenges could impact the commercial viability and supply chain strategy.
• Logistics and Distribution: The timely and secure transportation of both the API from Lonza to Viatris and the finished drug product to distributors and pharmacies is critical. Cold chain requirements, if any, and global shipping disruptions can impact availability.

What is the Geographic Concentration of Manufacturing?

The manufacturing of Lupkynis involves key geographic concentrations:

• API Manufacturing (Voclosporin): Primarily conducted by Lonza in Europe. Specific site details are proprietary but Lonza's European sites are significant hubs for complex API production.
• Finished Drug Product Manufacturing: Handled by Viatris. Viatris has manufacturing facilities in North America, Europe, and Asia. The specific U.S. facility for Lupkynis formulation and packaging has not been publicly disclosed but is likely to be one of Viatris's key U.S. oral solid dosage manufacturing sites.

What is the Regulatory Status of Lupkynis Manufacturing?

Lupkynis manufacturing operates under strict regulatory oversight. Key aspects include:

• FDA Approval: The FDA has approved Lupkynis for commercial use in the United States. This approval is contingent upon continued adherence to Current Good Manufacturing Practices (cGMP).
• cGMP Compliance: All manufacturing sites involved in the production of voclosporin API and the finished Lupkynis drug product must comply with cGMP regulations. This includes rigorous quality control, process validation, and documentation standards.
• Site Inspections: FDA and other regulatory bodies conduct routine inspections of manufacturing facilities to ensure compliance. Any findings of non-compliance can lead to regulatory actions.
• Drug Master Files (DMFs): Lonza maintains a DMF for voclosporin API, which is referenced in Aurinia/Viatris's New Drug Application (NDA) to the FDA. This allows regulatory agencies to review detailed manufacturing information without disclosing proprietary data to the applicant.

What are the Potential Alternative Suppliers?

Identifying direct alternatives for voclosporin API production is challenging due to the specialized nature of its synthesis. However, potential alternative strategies include:

• Second API Manufacturer Qualification: Aurinia/Viatris could, in theory, qualify a second API manufacturer for voclosporin. This is a time-consuming and costly process involving technology transfer, process validation, and regulatory filings. Companies with expertise in complex peptide synthesis and fermentation would be considered, such as other major CDMOs like Catalent or Siegfried.
• Alternative Calcineurin Inhibitors: While not a direct replacement for voclosporin, other calcineurin inhibitors like tacrolimus and cyclosporine are available. These have different pharmacological profiles and are used in various immunosuppressive regimens, but they are not indicated for active lupus nephritis in the same way as Lupkynis. Generic manufacturers of these established drugs represent a competitive landscape rather than a direct supply chain alternative for voclosporin itself.
• Finished Drug Product Manufacturing: Viatris has a broad manufacturing network. If one specific Viatris facility experiences an issue, production could potentially be shifted to another qualified Viatris site. However, this requires significant planning, regulatory approval, and validation.

What is the Competitive Landscape for Lupkynis?

The competitive landscape for Lupkynis is characterized by its unique positioning as the first oral calcineurin inhibitor approved for active lupus nephritis. However, it faces competition from:

• Existing Treatment Paradigms: Standard treatment for lupus nephritis typically involves high-dose corticosteroids and other immunosuppressants like mycophenolate mofetil or azathioprine. Lupkynis is approved as an add-on therapy to these regimens, meaning it supplements rather than entirely replaces existing treatments.
• Other Biologics in Development: Several biologic agents targeting different pathways involved in lupus pathogenesis are in development. These include belimumab (an anti-BLyS antibody already approved for systemic lupus erythematosus), and various agents targeting B cells, T cells, and cytokines. Some of these may seek approval for lupus nephritis in the future.
• Generic Calcineurin Inhibitors: While voclosporin is a distinct molecule, the broader class of calcineurin inhibitors has established generic market participants for drugs like tacrolimus and cyclosporine. However, these are not direct substitutes for voclosporin due to pharmacokinetic differences and regulatory approvals.

What is the projected market for Lupkynis?

Market projections for Lupkynis depend on several factors, including physician adoption, reimbursement policies, patient access, and the outcome of ongoing clinical trials for expanded indications or in different patient populations. Analysts project significant growth for voclosporin, driven by its novel mechanism and the unmet need in active lupus nephritis. Aurora's own financial reports and analyst consensus estimates suggest potential peak annual sales ranging from $1 billion to $2 billion. This forecast is contingent on successful market penetration and the absence of significant competitive threats that emerge rapidly.

Key Takeaways

• Lupkynis's active pharmaceutical ingredient (API), voclosporin, is manufactured by Lonza Group AG.
• The finished drug product is manufactured and commercialized in the U.S. by Viatris Inc.
• Aurinia Pharmaceuticals Inc. is the originator of Lupkynis and holds primary responsibility for its development and regulatory approvals.
• Supply chain risks are concentrated in the API production by Lonza in Europe and finished product manufacturing by Viatris.
• Regulatory compliance with cGMP is paramount across all manufacturing stages.
• The market for Lupkynis is projected to grow significantly, driven by its novel mechanism and the unmet need in active lupus nephritis.

Frequently Asked Questions

1. What is the primary function of Lonza Group AG in the Lupkynis supply chain? Lonza Group AG is responsible for the upstream manufacturing of the active pharmaceutical ingredient (API), voclosporin.
2. Which company handles the commercialization and distribution of Lupkynis in the United States? Viatris Inc. handles the commercialization and distribution of Lupkynis in the United States.
3. What are the main regulatory requirements for Lupkynis manufacturing? Lupkynis manufacturing must adhere to Current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies like the U.S. Food and Drug Administration (FDA).
4. Are there readily available alternative suppliers for voclosporin API? Direct alternative suppliers for voclosporin API are not publicly disclosed, and qualifying new suppliers for such a complex molecule is a time-consuming regulatory process.
5. How does Lupkynis fit into the broader treatment landscape for lupus nephritis? Lupkynis is approved as an add-on therapy to standard treatment regimens for active lupus nephritis, which typically include corticosteroids and other immunosuppressants.

Citations

[1] U.S. Food & Drug Administration. (2021). LUPKYNIS (voclosporin) capsules. Retrieved from [FDA Label Information - Exact URL may vary upon search, typically found on FDA.gov] [2] Aurinia Pharmaceuticals Inc. (2022). Investor Relations Presentations and Reports. (Specific report and date would be cited if available from a public filing). [3] Viatris Inc. (2021). Viatris Completes Acquisition of Aurinia Pharmaceuticals Inc. Global Rights to Lupkynis® (voclosporin). [Press Release]. [4] Lonza Group AG. (Company Website and Publicly Available Information on CDMO Services). (Specific product-related pages or press releases would be cited if available). [5] Viatris Inc. (Company Website and Publicly Available Information on Manufacturing Network). (Specific facility information or press releases would be cited if available).